STELLAR Failure Prompts Cell Therapeutics To Amend Next Xyotax Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive non-inferiority to standard paclitaxel is silver lining to STELLAR 3, firm says. Potential amendment to the second-line STELLAR 2 trial to use non-inferiority as the primary endpoint will be discussed with FDA. CTI plans to present results from STELLAR 3 at ASCO meeting in May.
You may also be interested in...
Cell Therapeutics Will Pursue Xyotax Approval For Women With NSCLC
Despite having missed the primary endpoints in both STELLAR 3 and 4 trials, Cell Therapeutics plans to seek approval for Xyotax as first-line therapy for women with poor performance status, advanced non-small cell lung cancer.
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.